SmartZyme BioPharma Company
Better Continuous Glucose Monitors with a Next-Generation Glucose Sensing Enzyme SmartZyme BioPharma, Inc. is a medical technology company enabling a seamless leap to better performing glucose monitoring for people with diabetes. The company is accelerating the integration of SmartZyme's next-generation glucose-sensing enzyme into continuous glucose monitoring devices. A next-generation enzyme means no more signal mediators for the most cost-effective manufacturing; no more hypoglycemic errors for a superior safety profile; and no more fingersticks for the best quality of life. SmartZyme is an OrbiMed portfolio company.
Industry:
Geroscience
Headquarters:
New York, New York, United States
Zip:
11-50
Founded Date:
2013-01-01
Employees Number:
11-50
Acquisitions Number:
2
Investors Number:
8000000
Total Funding:
$1M to $10M
Estimated Revenue:
$1M to $10M
Last Funding Date:
Series B
Last Funding Type:
Series B
Register and Claim Ownership